(1) This instrument is the National Health (Minimum Stockholding) Amendment Determination (No. 1) 2024.

(2) This instrument may also be cited as PB 10 of 2024.

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	1 February 2024.	1 February 2024
2. Schedule 1	1 February 2024.	1 February 2024
3. Schedule 2	1 June 2024.	1 June 2024

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99AEKC(2) of the National Health Act 1953.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 February 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1

Omit:

Aciclovir	Tablet 200 mg	Oral	GenRx Aciclovir	between 1 December 2023 and 31 December 2023—0 months stock by reference to usual demand
Alendronic acid with colecalciferol	Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol	Oral	Fosamax Plus 70 mg/140 mcg	between 1 July 2023 and 31 December 2023—1.5 months stock by reference to usual demand
Alendronic acid with colecalciferol	Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol	Oral	Fosamax Plus	between 1 July 2023 and 31 December 2023—1.5 months stock by reference to usual demand

2 Schedule 1

Omit:

Allopurinol

Tablet 300 mg

Oral

Allopurinol APOTEX

between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand

3 Schedule 1

Omit:

Amisulpride	Tablet 100 mg	Oral	Amisulpride 100 Winthrop	Between 1 October 2023 and 31 January 2024—0 months stock by reference to usual demand
Amitriptyline	Tablet containing amitriptyline hydrochloride 10 mg	Oral	APX‑Amitriptyline	between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand

4 Schedule 1

Omit:

Amlodipine	Tablet 10 mg (as besilate)	Oral	Amlodipine Amneal	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Amlodipine	Tablet 5 mg (as besilate)	Oral	Amneal	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

5 Schedule 1

Omit:

Amoxicillin with clavulanic acid	Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)	Oral	Amoxyclav AN 500/125	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Amoxicillin with clavulanic acid	Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)	Oral	Amoxyclav AN 875/125	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

6 Schedule 1

After:

Aripiprazole

Tablet 10 mg

Oral

APO‑Aripiprazole

3 months stock by reference to usual demand

insert:

Aripiprazole

Tablet 10 mg

Oral

Aripic Aripiprazole

between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand

7 Schedule 1

Omit:

Aripiprazole

Tablet 30 mg

Oral

Aripiprazole generichealth

between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

8 Schedule 1

Omit:

Atenolol

Tablet 50 mg

Oral

Atenolol Amneal

between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

9 Schedule 1

After:

Atomoxetine

Capsule 80 mg (as hydrochloride)

Oral

APO‑Atomoxetine

3 months stock by reference to usual demand

insert:

Atorvastatin

Tablet 10 mg (as calcium)

Oral

Atorvastatin GH

between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand

10 Schedule 1

After:

Atorvastatin

Tablet 20 mg (as calcium)

Oral

Atorvastatin GH

Between 1 October 2023 and 29 February 2024—0 months stock by reference to usual demand

insert:

Atorvastatin

Tablet 40 mg (as calcium)

Oral

Atorvastatin GH

between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand

11 Schedule 1

Omit:

Azathioprine

Tablet 50 mg

Oral

Azathioprine GH

Between 1 October 2023 and 31 January 2024—0 months stock by reference to usual demand

12 Schedule 1

Omit:

Bleomycin

Powder for injection containing bleomycin sulfate 15,000 I.U.

Injection

CIPLA BLEOMYCIN

between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

13 Schedule 1

Omit:

Bosentan	Tablet 62.5 mg (as monohydrate)	Oral	Bosentan Cipla	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Calcitriol	Capsule 0.25 microgram	Oral	Calcitriol AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

14 Schedule 1

Omit:

Candesartan	Tablet containing candesartan cilexetil 4 mg	Oral	APO‑Candesartan	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand
Candesartan	Tablet containing candesartan cilexetil 4 mg	Oral	CANDESAN	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand
Candesartan	Tablet containing candesartan cilexetil 8 mg	Oral	APO‑Candesartan	between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand
Candesartan	Tablet containing candesartan cilexetil 8 mg	Oral	CANDESAN	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand

15 Schedule 1

After:

Calcium

Tablet, chewable, 500 mg (as carbonate)

Oral

Cal‑500

after 30 November 2023—6 months stock by reference to usual PBS demand

insert:

Capecitabine

Tablet 150 mg

Oral

Capecitabine-DRLA

between 1 February 2024 and 30 June 2024—0 months stock by reference to usual demand

16 Schedule 1

Omit:

Cefaclor	Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL	Oral	APO‑Cefaclor	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Cefaclor	Tablet (sustained release) 375 mg (as monohydrate)	Oral	APO‑Cefaclor CD	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Cefalexin	Capsule 500 mg (as monohydrate)	Oral	APO‑Cephalexin	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand
Cefazolin	Powder for injection 2 g (as sodium)	Injection	Cefazolin‑AFT	between 1 December 2023 and 31 December 2023—0 months stock by reference to usual demand
Cefepime	Powder for injection 1 g (as hydrochloride)	Injection	Cefepime Alphapharm	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Cefepime	Powder for injection 1 g (as hydrochloride)	Injection	Cefepime‑AFT	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Cefepime	Powder for injection 2 g (as hydrochloride)	Injection	Cefepime Alphapharm	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Ceftriaxone	Powder for injection 1 g (as sodium)	Injection	Ceftriaxone‑AFT	between 1 December 2023 and 31 December 2023—0 months stock by reference to usual demand
Ceftriaxone	Powder for injection 2 g (as sodium)	Injection	Ceftriaxone‑AFT	between 1 December 2023 and 31 December 2023—0 months stock by reference to usual demand

17 Schedule 1

After:

Carmellose with glycerin

Eye drops containing carmellose sodium 5 mg with glycerin 9 mg per mL, 15 mL

Application to the Eye

Optive

4 months stock by reference to usual PBS demand

insert:

Ceftriaxone

Powder for injection 2 g (as sodium)

Injection

Ceftriaxone Viatris

after 31 May 2024—6 months stock by reference to usual demand of both Ceftriaxone Viatris and Ceftriaxone Alphapharm added together

18 Schedule 1

Omit:

Citalopram	Tablet 10 mg (as hydrobromide)	Oral	Citalopram AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Citalopram	Tablet 20 mg (as hydrobromide)	Oral	Citalopram AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Citalopram	Tablet 40 mg (as hydrobromide)	Oral	Citalopram AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

19 Schedule 1

Omit:

Clarithromycin

Tablet 250 mg

Oral

Clarithromycin AN

between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

20 Schedule 1

Omit:

Cyproterone	Tablet containing cyproterone acetate 100 mg	Oral	APO‑Cyproterone	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Cyproterone	Tablet containing cyproterone acetate 100 mg	Oral	Cyprone 100	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Cyproterone	Tablet containing cyproterone acetate 100 mg	Oral	GenRx Cyproterone Acetate	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Cyproterone	Tablet containing cyproterone acetate 50 mg	Oral	APO‑Cyproterone	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Cyproterone	Tablet containing cyproterone acetate 50 mg	Oral	Cyprone 50	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Cyproterone	Tablet containing cyproterone acetate 50 mg	Oral	GenRx Cyproterone Acetate	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

21 Schedule 1

Omit:

Desvenlafaxine	Tablet (modified release) 100 mg	Oral	Desvenlafaxine Actavis	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Desvenlafaxine	Tablet (modified release) 50 mg	Oral	Desvenlafaxine Actavis	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Dexamethasone with framycetin and gramicidin	Ear drops containing dexamethasone 500 micrograms (as sodium metasulfobenzoate), framycetin sulfate 5 mg and gramicidin 50 micrograms per mL, 8 mL	Application to the Ear	Sofradex	between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand

22 Schedule 1

Omit:

Diclofenac

Tablet (enteric coated) containing diclofenac sodium 25 mg

Oral

Diclofenac AN

between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

23 Schedule 1

Omit:

Diclofenac

Tablet (enteric coated) containing diclofenac sodium 50 mg

Oral

Diclofenac AN

between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

24 Schedule 1

After:

Domperidone

Tablet 10 mg

Oral

Motilium

between 1 July 2023 and 31 March 2024—4 months stock by reference to usual PBS demand

insert:

Dosulepin

Capsule containing dosulepin hydrochloride 25 mg

Oral

Dosulepin Viatris

after 31 May 2024—6 months stock by reference to usual demand of both Dosulepin Viatris and Dosulepin Mylan added together

25 Schedule 1

Omit:

Doxycycline	Tablet 100 mg (as hyclate)	Oral	Doxsig	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand
Doxycycline	Tablet 100 mg (as monohydrate)	Oral	APO‑Doxycycline	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Doxycycline	Tablet 50 mg (as hyclate)	Oral	APX‑Doxycycline	between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand

26 Schedule 1

Omit:

Doxycycline

Tablet 50 mg (as monohydrate)

Oral

APO‑Doxycycline

between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

27 Schedule 1

After:

Enalapril

Tablet containing enalapril maleate 10 mg

Oral

APO‑Enalapril

4 months stock by reference to usual demand

insert:

Enalapril

Tablet containing enalapril maleate 10 mg

Oral

Enalapril generichealth

between 1 February 2024 and 31 May 2024—0 months stock by reference to usual demand

28 Schedule 1

After:

Enalapril

Tablet containing enalapril maleate 5 mg

Oral

APO‑Enalapril

4 months stock by reference to usual demand

insert:

Enalapril

Tablet containing enalapril maleate 5 mg

Oral

Enalapril generichealth

between 1 February 2024 and 31 May 2024—0 months stock by reference to usual demand

29 Schedule 1

Omit:

Esomeprazole	Capsule (enteric) 20 mg (as magnesium)	Oral	Noxicid Caps	between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand
Esomeprazole	Capsule (enteric) 40 mg (as magnesium)	Oral	Noxicid Caps	between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand
Esomeprazole	Tablet (enteric coated) 20 mg (as magnesium trihydrate)	Oral	Esomeprazole Apotex	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Esomeprazole	Tablet (enteric coated) 40 mg (as magnesium trihydrate)	Oral	Esomeprazole Apotex	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

30 Schedule 1

Omit:

Ezetimibe with simvastatin	Tablet 10 mg‑10 mg	Oral	EZEVYT 10/10	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg‑10 mg	Oral	Vytorin	between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg‑10 mg	Oral	Zeklen 10/10 mg	between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand

31 Schedule 1

Omit:

Ezetimibe with simvastatin	Tablet 10 mg‑20 mg	Oral	EZEVYT 10/20	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg‑20 mg	Oral	Vytorin	between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg‑20 mg	Oral	Zeklen 10/20 mg	between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand

32 Schedule 1

Omit:

Ezetimibe with simvastatin	Tablet 10 mg‑40 mg	Oral	EZEVYT 10/40	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg‑40 mg	Oral	Vytorin	between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg‑40 mg	Oral	Zeklen 10/40 mg	between 1 July 2023 and 31 December 2023—2.5 months stock by reference to usual demand

33 Schedule 1

Omit:

Ezetimibe with simvastatin	Tablet 10 mg‑80 mg	Oral	EZEVYT 10/80	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg‑80 mg	Oral	Vytorin	between 1 July 2023 and 31 December 2023—2 months stock by reference to usual demand
Ezetimibe with simvastatin	Tablet 10 mg‑80 mg	Oral	Zeklen 10/80 mg	between 1 July 2023 and 31 December 2023—1.5 months stock by reference to usual demand
Famciclovir	Tablet 125 mg	Oral	Famciclovir‑GA	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Famciclovir	Tablet 250 mg	Oral	Famciclovir‑GA	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Famciclovir	Tablet 500 mg	Oral	Famciclovir‑GA	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

34 Schedule 1

Omit:

Flucloxacillin

Capsule 250 mg (as sodium monohydrate)

Oral

APO‑Flucloxacillin

between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

35 Schedule 1

Omit:

Fluorometholone

Eye drops containing fluorometholone acetate 1 mg per mL, 5 mL

Application to the Eye

Flarex

4 months stock by reference to usual PBS demand

substitute:

Fluorometholone

Eye drops containing fluorometholone acetate 1 mg per mL, 5 mL

Application to the Eye

Flarex

between 1 February 2024 and 31 July 2024—0 months stock by reference to usual PBS demand

36 Schedule 1

Omit:

Furosemide	Tablet 20 mg	Oral	FUROSEMIDE AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Furosemide	Tablet 20 mg	Oral	Urex‑M	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Furosemide	Tablet 40 mg	Oral	FUROSEMIDE AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Furosemide	Tablet 40 mg	Oral	Urex	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Gabapentin	Capsule 100 mg	Oral	Gabapentin APOTEX	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Gabapentin	Capsule 100 mg	Oral	GAPENTIN	between 1 July 2023 and 31 December 2023—3.5 months stock by reference to usual demand
Gabapentin	Capsule 300 mg	Oral	Gabapentin APOTEX	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Gabapentin	Capsule 300 mg	Oral	GAPENTIN	between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand
Gabapentin	Capsule 400 mg	Oral	Gabapentin APOTEX	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

37 Schedule 1

Omit:

Gabapentin

Tablet 600 mg

Oral

Gabapentin AN

between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

38 Schedule 1

Omit:

Gemfibrozil

Tablet 600 mg

Oral

Lipigem

between 1 July 2023 and 31 December 2023—2 months stock by reference to usual demand

39 Schedule 1

Omit:

Glimepiride

Tablet 2 mg

Oral

Amaryl

between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

40 Schedule 1

Omit:

Glimepiride

Tablet 3 mg

Oral

Amaryl

Between 1 October 2023 and 31 December 2023—0 months stock by reference to usual demand

41 Schedule 1

Omit:

Ibuprofen

Tablet 400 mg

Oral

APO‑Ibuprofen 400

between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand

42 Schedule 1

Omit:

Ipratropium	Nebuliser solution containing ipratropium bromide 250 micrograms (as monohydrate) in 1 mL single dose units, 30	Inhalation	APO‑Ipratropium	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Ipratropium	Nebuliser solution containing ipratropium bromide 500 micrograms (as monohydrate) in 1 mL single dose units, 30	Inhalation	APO‑Ipratropium	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Irbesartan with hydrochlorothiazide	Tablet 300 mg‑25 mg	Oral	AVSARTAN HCT 300/25	between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand
Irbesartan	Tablet 300 mg	Oral	Irbesartan AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Irbesartan	Tablet 75 mg	Oral	Irbesartan AMNEAL	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Irbesartan	Tablet 75 mg	Oral	Irbesartan AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Irinotecan	I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL	Injection	MEDITAB IRINOTECAN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Irinotecan	I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL	Injection	MEDITAB IRINOTECAN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Isosorbide mononitrate	Tablet 60 mg (sustained release)	Oral	Isosorbide AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Isosorbide mononitrate	Tablet 60 mg (sustained release)	Oral	Monodur 60 mg	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Isotretinoin	Capsule 10 mg	Oral	Rocta 10	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Isotretinoin	Capsule 20 mg	Oral	Rocta 20	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Lamotrigine	Tablet 100 mg	Oral	APO‑Lamotrigine	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Lamotrigine	Tablet 200 mg	Oral	APO‑Lamotrigine	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Lamotrigine	Tablet 25 mg	Oral	APO‑Lamotrigine	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Lamotrigine	Tablet 50 mg	Oral	APO‑Lamotrigine	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

43 Schedule 1

After:

Insect allergen extract‑yellow jacket venom

Injection set containing 550 micrograms with diluent

Injection

Hymenoptera Yellow Jacket Venom

after 30 November 2023—6 months stock by reference to usual PBS demand

insert:

Lamivudine with zidovudine

Tablet 150 mg-300 mg

Oral

Lamivudine/Zidovudine Viatris 150/300

after 31 May 2024—4 months stock by reference to usual demand of both Lamivudine/Zidovudine Viatris 150/300 and Lamivudine 150 mg + Zidovudine 300 mg Alphapharm added together

44 Schedule 1

Omit:

Levonorgestrel with ethinylestradiol	Pack containing 21 tablets 150 micrograms‑30 micrograms and 7 inert tablets	Oral	Monofeme 28	Between 1 October 2023 and 31 December 2023—0 months stock by reference to usual demand
Levonorgestrel with ethinylestradiol	Pack containing 21 tablets 150 micrograms‑30 micrograms and 7 inert tablets	Oral	Lenest 30 ED	between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand

45 Schedule 1

Omit:

Meloxicam	Capsule 15 mg	Oral	Chem mart Meloxicam	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Meloxicam	Capsule 15 mg	Oral	Terry White Chemists Meloxicam	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Meloxicam	Capsule 7.5 mg	Oral	Chem mart Meloxicam	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Meloxicam	Capsule 7.5 mg	Oral	Terry White Chemists Meloxicam	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Meloxicam	Tablet 7.5 mg	Oral	APX‑Meloxicam	between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand

46 Schedule 1

Omit:

Metformin	Tablet (extended release) containing metformin hydrochloride 500 mg	Oral	Metformin XR 500 APOTEX	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Metformin	Tablet containing metformin hydrochloride 1 g	Oral	APO‑Metformin 1000	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Metformin	Tablet containing metformin hydrochloride 1 g	Oral	Metformin AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Metformin	Tablet containing metformin hydrochloride 500 mg	Oral	APO‑Metformin 500	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Metformin	Tablet containing metformin hydrochloride 500 mg	Oral	Metformin AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Metformin	Tablet containing metformin hydrochloride 850 mg	Oral	APO‑Metformin 850	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Metformin	Tablet containing metformin hydrochloride 850 mg	Oral	Chem mart Metformin	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Metformin	Tablet containing metformin hydrochloride 850 mg	Oral	Metformin AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Metformin	Tablet containing metformin hydrochloride 850 mg	Oral	Terry White Chemists Metformin	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Methotrexate	Solution concentrate for I.V. infusion 1000 mg in 10 mL vial	Injection	Pfizer Australia Pty Ltd	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

47 Schedule 1

After:

Methoxyflurane

Liquid for inhalation 999 mg per g, 3 ml (with inhaler)

Inhalation by mouth

Penthrox

6 months stock by reference to usual PBS demand

insert:

Methylprednisolone

Powder for injection 40 mg (as sodium succinate)

Injection

Methylpred

between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand

48 Schedule 1

Omit:

Metoclopramide

Injection containing 10 mg metoclopramide hydrochloride (as monohydrate) in 2 mL

Injection

Maxolon

between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

49 Schedule 1

Omit:

Mirtazapine	Tablet 15 mg (orally disintegrating)	Oral	Mirtazapine AN ODT	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Mirtazapine	Tablet 15 mg	Oral	APO‑Mirtazapine	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Mirtazapine	Tablet 30 mg (orally disintegrating)	Oral	Mirtazapine AN ODT	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Mirtazapine	Tablet 30 mg	Oral	APO‑Mirtazapine	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Mirtazapine	Tablet 30 mg	Oral	Mirtazon	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Mirtazapine	Tablet 45 mg (orally disintegrating)	Oral	Mirtazapine AN ODT	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Mirtazapine	Tablet 45 mg	Oral	APO‑Mirtazapine	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Mirtazapine	Tablet 45 mg	Oral	Mirtazon	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

50 Schedule 1

Omit:

Moclobemide	Tablet 150 mg	Oral	APO‑Moclobemide	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Moclobemide	Tablet 150 mg	Oral	Moclobemide AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Moclobemide	Tablet 300 mg	Oral	APO‑Moclobemide	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Moclobemide	Tablet 300 mg	Oral	Moclobemide AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

51 Schedule 1

After:

Moxonidine

Tablet 200 micrograms

Oral

Moxonidine Viatris

4 months stock by reference to usual demand of both Moxonidine Viatris and Moxonidine MYL added together

insert:

Moxonidine	Tablet 400 micrograms	Oral	Moxonidine Viatris	4 months stock by reference to usual demand of both Moxonidine Viatris and Moxonidine MYL added together
Mycophenolic acid	Capsule containing mycophenolate mofetil 250 mg	Oral	CellCept	between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand
Mycophenolic acid	Tablet containing mycophenolate mofetil 500 mg	Oral	CellCept	between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand

52 Schedule 1

Omit:

Olanzapine	Tablet 10 mg (orally disintegrating)	Oral	APO‑Olanzapine ODT	between 1 July 2023 and 31 December 2023—3.5 months stock by reference to usual demand
Olanzapine	Tablet 15 mg (orally disintegrating)	Oral	APO‑Olanzapine ODT	between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand

53 Schedule 1

After:

Norfloxacin

Tablet 400 mg

Oral

APO‑Norfloxacin

2.5 months stock by reference to usual demand

insert:

Olanzapine

Tablet 10 mg (orally disintegrating)

Oral

Zypine ODT

(a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 10 mg, Oral;

(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 10 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 10 mg (orally disintegrating), Oral, added together

54 Schedule 1

After:

Olanzapine

Tablet 15 mg (orally disintegrating)

Oral

PRYZEX ODT

(a) between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand

(b) after 31 December 2023—3.5 months stock by reference to usual demand

insert:

Olanzapine

Tablet 15 mg (orally disintegrating)

Oral

Zypine ODT

(a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral;

(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 15 mg (orally disintegrating), Oral, added together.

Olanzapine

Tablet 20 mg (orally disintegrating)

Oral

Zypine ODT

(a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral;

(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 20 mg (orally disintegrating), Oral, added together

55 Schedule 1

Omit:

Olanzapine

Tablet 5 mg (orally disintegrating)

Oral

Olanzapine ODT generichealth 5

Between 1 October 2023 and 31 December 2023—0 months stock by reference to usual demand

56 Schedule 1

After:

Olanzapine

Tablet 5 mg (orally disintegrating)

Oral

APO‑Olanzapine ODT

3 months stock by reference to usual demand

insert:

Olanzapine

Tablet 5 mg (orally disintegrating)

Oral

Zypine ODT

(a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral;

(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 5 mg (orally disintegrating), Oral, added together

57 Schedule 1

Omit:

Olmesartan with hydrochlorothiazide

Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg

Oral

APX‑Olmesartan/HCTZ

between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand

58 Schedule 1

Omit:

Ondansetron	Tablet (orally disintegrating) 4 mg	Oral	APO‑Ondansetron ODT	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Ondansetron	Tablet (orally disintegrating) 4 mg	Oral	Ondansetron AN ODT	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Ondansetron	Tablet (orally disintegrating) 8 mg	Oral	APO‑Ondansetron ODT	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Ondansetron	Tablet (orally disintegrating) 8 mg	Oral	Ondansetron AN ODT	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Ondansetron	Tablet 4 mg (as hydrochloride dihydrate)	Oral	Ondansetron AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Ondansetron	Tablet 4 mg (as hydrochloride dihydrate)	Oral	Ondansetron APOTEX	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Ondansetron	Tablet 8 mg (as hydrochloride dihydrate)	Oral	Ondansetron AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Ondansetron	Tablet 8 mg (as hydrochloride dihydrate)	Oral	Ondansetron APOTEX	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

59 Schedule 1

After:

Oxycodone

Oral solution containing oxycodone hydrochloride 1 mg per mL, 1 mL

Oral

OxyNorm Liquid 1mg/mL

4 months stock by reference to usual PBS demand

insert:

Oxycodone

Tablet containing oxycodone hydrochloride 5 mg

Oral

Oxycodone Viatris

after 28 February 2024—6 months stock by reference to usual demand of both Oxycodone Viatris and Oxycodone Mylan added together

60 Schedule 1

Omit:

Pantoprazole	Tablet (enteric coated) 20 mg (as sodium sesquihydrate)	Oral	Pantoprazole APOTEX	between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand
Pantoprazole	Tablet (enteric coated) 20 mg (as sodium sesquihydrate)	Oral	Sozol	between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand
Pantoprazole	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	Oral	Pantoprazole AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Pantoprazole	Tablet (enteric coated) 40 mg (as sodium sesquihydrate)	Oral	Pantoprazole APOTEX	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand

61 Schedule 1

After:

Pantoprazole

Tablet (enteric coated) 40 mg (as sodium sesquihydrate)

Oral

Sozol

(a) between 1 July 2023 and 31 December 2023—4.5 months stock by reference to usual demand

(b) after 31 December 2023—5.5 months stock by reference to usual demand

insert:

Paraffin with retinol palmitate

Eye ointment, compound, containing liquid paraffin, light liquid paraffin, wool fat, white soft paraffin and retinol palmitate, 5 g

Application to the Eye

VitA-POS

between 1 April 2024 and 30 September 2024—0 months stock by reference to usual demand

62 Schedule 1

Omit:

Paroxetine	Tablet 20 mg (as hydrochloride)	Oral	Paroxetine AN	Between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Pegfilgrastim	Injection 6 mg in 0.6 mL single use pre-filled syringe	Injection	Ristempa	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

63 Schedule 1

Omit:

Perindopril	Tablet containing perindopril erbumine 4 mg	Oral	Perindopril generichealth	Between 1 October 2023 and 31 January 2024—0 months stock by reference to usual demand
Perindopril	Tablet containing perindopril erbumine 8 mg	Oral	Perindopril generichealth	Between 1 October 2023 and 31 January 2024—0 months stock by reference to usual demand
Perindopril with amlodipine	Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate)	Oral	APO‑Perindopril Arginine/Amlodipine 5/10	between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand

64 Schedule 1

Omit:

Pravastatin	Tablet containing pravastatin sodium 10 mg	Oral	APO‑Pravastatin	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Pravastatin	Tablet containing pravastatin sodium 20 mg	Oral	APO‑Pravastatin	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Pravastatin	Tablet containing pravastatin sodium 40 mg	Oral	APO‑Pravastatin	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Pravastatin	Tablet containing pravastatin sodium 80 mg	Oral	APO‑Pravastatin	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

65 Schedule 1

Omit:

Pregabalin

Capsule 25 mg

Oral

LYPRALIN

between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

66 Schedule 1

Omit:

Pregabalin

Capsule 300 mg

Oral

LYPRALIN

between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

67 Schedule 1

After:

Probenecid

Tablet 500 mg

Oral

Pro‑Cid

after 30 November 2023—6 months stock by reference to usual PBS demand

insert:

Prochlorperazine

Tablet containing prochlorperazine maleate 5 mg

Oral

Stemzine

between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand

68 Schedule 1

Omit:

Quetiapine	Tablet 100 mg (as fumarate)	Oral	Quetiapine AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Quetiapine	Tablet 300 mg (as fumarate)	Oral	Quetiapine AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

69 Schedule 1

Omit:

Rabeprazole	Tablet containing rabeprazole sodium 20 mg (enteric coated)	Oral	APO‑Rabeprazole	between 1 July 2023 and 31 December 2023—5 months stock by reference to usual demand
Raloxifene	Tablet containing raloxifene hydrochloride 60 mg	Oral	APO‑Raloxifene	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

70 Schedule 1

Omit:

Ramipril	Tablet 2.5 mg	Oral	APO‑Ramipril	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand
Ramipril	Tablet 5 mg	Oral	Prilace	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand

71 Schedule 1

Omit:

Ramipril

Capsule 1.25 mg

Oral

APO‑Ramipril

between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

72 Schedule 1

Omit:

Risperidone

Tablet 1 mg

Oral

APO‑Risperidone

between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand

73 Schedule 1

Omit:

Risperidone	Tablet 4 mg	Oral	Rispa	between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand
Rizatriptan	Tablet (orally disintegrating) 10 mg (as benzoate)	Oral	Rizatriptan AN ODT	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Rosuvastatin	Tablet 10 mg (as calcium)	Oral	APX‑Rosuvastatin	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand
Rosuvastatin	Tablet 5 mg (as calcium)	Oral	APX‑Rosuvastatin	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand
Rosuvastatin	Tablet 5 mg (as calcium)	Oral	Crosuva 5	between 1 July 2023 and 31 December 2023—5.5 months stock by reference to usual demand

74 Schedule 1

After:

Risperidone

Tablet 3 mg

Oral

Risperidone generichealth

between 1 November 2023 and 31 March 2024—0 months stock by reference to usual demand

insert:

Risperidone

Tablet 4 mg

Oral

Risperidone generichealth

between 1 February 2024 and 30 April 2024—0 months stock by reference to usual demand

75 Schedule 1

Omit:

Salbutamol

Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30

Inhalation

Salbutamol AN

between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

76 Schedule 1

Omit:

Sertraline	Tablet 100 mg (as hydrochloride)	Oral	Sertraline AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Sertraline	Tablet 50 mg (as hydrochloride)	Oral	Sertraline AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Sildenafil	Tablet 20 mg (as citrate)	Oral	Sildenafil AN PHT 20	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand

77 Schedule 1

Omit:

Sotalol

Tablet containing sotalol hydrochloride 160 mg

Oral

APO‑Sotalol

between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

78 Schedule 1

Omit:

Sotalol

Tablet containing sotalol hydrochloride 80 mg

Oral

APO‑Sotalol

between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

79 Schedule 1

Omit:

Tacrolimus

Capsule 0.5 mg

Oral

Tacrograf

between 1 July 2023 and 31 December 2023—3 months stock by reference to usual demand

80 Schedule 1

Omit:

Temozolomide	Capsule 180 mg	Oral	Temodal	between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand
Temozolomide	Capsule 250 mg	Oral	Temodal	between 1 July 2023 and 31 December 2023—0 months stock by reference to usual demand

81 Schedule 1

After:

Tenofovir with emtricitabine

Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg

Oral

Tenofovir/Emtricitabine 300/200 APOTEX

3 months stock by reference to usual demand

insert:

Tenofovir with emtricitabine

Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg

Oral

Tenofovir Disoproxil Emtricitabine Viatris 300/200

after 30 April 2024—4 months stock by reference to usual demand of both Tenofovir Disoproxil Emtricitabine Viatris 300/200 and Tenofovir Disoproxil Emtricitabine Mylan 300/200 added together

82 Schedule 1

After:

Triglycerides, medium chain

Oral liquid 225 mL, 15 (K.Quik)

Oral

K.Quik

0 months stock by reference to usual PBS demand

insert:

Trimethoprim	Tablet 300 mg	Oral	Trimethoprim Viatris	after 30 April 2024—6 months stock by reference to usual demand of both Trimethoprim Viatris and Trimethoprim Mylan added together
Tropisetron	I.V. injection 5 mg (as hydrochloride) in 5 mL	Injection	Tropisetron-AFT	between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand

83 Schedule 1

After:

Voriconazole

Powder for oral suspension 40 mg per mL, 70 mL

Oral

Vfend

4 months stock by reference to usual PBS demand

insert:

Voriconazole

Tablet 200 mg

Oral

Vfend

between 1 February 2024 and 31 March 2024—0 months stock by reference to usual demand

84 Schedule 1

Omit:

Ziprasidone	Capsule 20 mg (as hydrochloride)	Oral	APO‑Ziprasidone	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Ziprasidone	Capsule 40 mg (as hydrochloride)	Oral	APO‑Ziprasidone	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Ziprasidone	Capsule 60 mg (as hydrochloride)	Oral	APO‑Ziprasidone	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Ziprasidone	Capsule 80 mg (as hydrochloride)	Oral	APO‑Ziprasidone	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand

Schedule 2—Amendments commencing 1 June 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1

After:

Chloramphenicol

Eye drops 5 mg per mL, 10 mL

Application to the Eye

Chlorsig

4 months stock by reference to usual PBS demand

insert:

Chlorpromazine	Injection containing chlorpromazine hydrochloride 50 mg in 2 mL	Injection	Largactil	6 months stock by reference to usual PBS demand
Chlorpromazine	Oral solution containing chlorpromazine hydrochloride 25 mg per 5 mL, 100 mL	Oral	Largactil	6 months stock by reference to usual PBS demand
Chlorpromazine	Tablet containing chlorpromazine hydrochloride 100 mg	Oral	Largactil	6 months stock by reference to usual PBS demand

2 Schedule 1

Omit:

Chlorpromazine

Tablet containing chlorpromazine hydrochloride 25 mg

Oral

Largactil

4 months stock by reference to usual PBS demand

substitute:

Chlorpromazine

Tablet containing chlorpromazine hydrochloride 25 mg

Oral

Largactil

6 months stock by reference to usual PBS demand

3 Schedule 1

After:

Paraffin with retinol palmitate

Eye ointment, compound, containing liquid paraffin, light liquid paraffin, wool fat, white soft paraffin and retinol palmitate, 5 g

Application to the Eye

VitA-POS

between 1 April 2024 and 30 September 2024—0 months stock by reference to usual demand

insert:

Periciazine

Tablet 10 mg

Oral

Neulactil

6 months stock by reference to usual PBS demand

4 Schedule 1

Omit:

Periciazine

Tablet 2.5 mg

Oral

Neulactil

4 months stock by reference to usual PBS demand

substitute:

Periciazine

Tablet 2.5 mg

Oral

Neulactil

6 months stock by reference to usual PBS demand